Protagonist Therapeutics (PTGX) Net Income (2015 - 2026)

Protagonist Therapeutics has reported Net Income for 12 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Net Income rose 132.46% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.7 million (down 304.31% YoY) and the FY2025 annual result came in at -$130.1 million, down 147.3% from the prior year.
• Net Income improved to $3.8 million in Q1 2026 per PTGX's latest filing, from -$44.4 million in the prior quarter.
• Over five years, Net Income peaked at $207.4 million in Q1 2024 and troughed at -$66.9 million in Q1 2022.
• A 5-year average of -$5.4 million and a median of -$33.7 million in 2023 frame the typical range for Net Income.
• The sharpest annual moves came in 2022 and 2024: Net Income tumbled 178.95% in 2022, then soared 714.87% in 2024.
• Over 5 years, Net Income stood at -$34.9 million in 2022, then soared by 225.69% to $43.9 million in 2023, then jumped by 199.7% to $131.6 million in 2024, then sank by 133.72% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered $3.8 million, -$44.4 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.